Antibodies that target tumor necrosis factor are effective at inducing and maintaining remission in both Crohn's disease (infliximab, adalimumab and certolizumab) and ulcerative colitis (infliximab). The results of a randomized controlled trial of adalimumab for inducing remission in moderately to severely active ulcerative colitis have now been published.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hanauer, S. B. et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323–333 (2006).
Colombel, J. F. et al. Adalimumab for maintenance of clinical response and clinical remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).
Fiorino, G. et al. Adalimumab in ulcerative colitis: hypes and hopes. Expert Opin. Biol. Ther. 11, 109–116 (2011).
Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut doi: 10.1136/gut.2010.221127.
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
Järnerot, G. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805–1811 (2005).
Sandborn, W. J. et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137, 1250–1260 (2009).
Oussalah, A. et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am. J. Gastroenterol. 105, 2617–2625 (2010).
Menter, A. et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 63, 448–456 (2010).
Weisman, M. H. et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 25, 1700–1721 (2003).
Efficacy and Safety of Adalimumab in Subjects with Moderately to Severaly Active Ulcerative Colitis. ClinicalTrials.gov [online], (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Armuzzi receives grant/research support from Abbott, Chiesi, Ferring, Merck/Schering Plough and Nycomed, and acts as a consultant for Abbot and Merck/Schering Plough. D. Pugliese receives grant/research support from Ferring.
Rights and permissions
About this article
Cite this article
Armuzzi, A., Pugliese, D. Adalimumab for ulcerative colitis—is the glass half empty or half full?. Nat Rev Gastroenterol Hepatol 8, 249–251 (2011). https://doi.org/10.1038/nrgastro.2011.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.48
